We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Given children's unique physiological and pharmacokinetic characteristics, the development of pediatric antibiotic formulations requires stringent controls.
Currently, the main clinical treatment methods for refractory Mycoplasma pneumoniae pneumonia (RMPP) after diagnosis include bronchoscope lavage, antibiotic therapy, glucocorticoid therapy, immune modulation treatment, antithrombotic therapy, and integrat
USAntibiotics, the sole-licensed American maker of penicillin-based Amoxil® (amoxicillin) and Augmentin® (amoxicillin clavulanate), announced that it has relaunched production of the nation's only Amoxicillin manufacturing facility. When it reaches...